Tag Archives: 340B program
If President Trump truly intends to control drug costs, fixing drug pricing formulas and enhancing existing penalties could reduce costs for both public and private payers.
March 31, 2017
Policies giving federal and state governments authority to set drug prices or limit price increases could have the unintended consequence of reducing the incentive to develop more effective drugs. However, certain regulatory reforms can address these concerns and encourage more robust...
July 11, 2016
In a previous blog, I described “the coming storm” I anticipated would develop around the 340B drug discount program. With the October 27 comment window steadily approaching, let’s take a look at what the rule says and what it could mean for interested stakeholders.
October 20, 2015